Carregant...
Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
PURPOSE OF REVIEW: Apolipoprotein C-III (apoC-III) is known to inhibit lipoprotein lipase (LPL) and function as an important regulator of triglyceride metabolism. In addition, apoC-III has also more recently been identified as an important risk factor for cardiovascular disease. This review summariz...
Guardat en:
| Publicat a: | Curr Atheroscler Rep |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer US
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6527792/ https://ncbi.nlm.nih.gov/pubmed/31111320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11883-019-0791-9 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|